Skip to main content

Advertisement

Springer Nature Link
Log in

Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

The discovery and targeting of genes mediating androgen-independence may lead to the development of novel therapies that delay progression of hormone refractory prostate cancer (HRPC). Clusterin is a stress-associated cell survival gene that increases after androgen ablation. Here, we review clusterin’s functional role in apoptosis and the use of antisense oligonucleotides (ASOs) against clusterin to enhance apoptosis in prostate cancer models. Immunostaining of tissue microarrays constructed from untreated and post-hormone treated radical prostatectomy specimens confirm that clusterin is highly expressed in virtually all HRPC cells, 80% of prostate cancer cells after neoadjuvant hormone therapy, but is low or absent (<20%) in untreated specimens. Overexpression of clusterin in LNCaP cells confers resistance to both androgen ablation and chemotherapy. Clusterin ASOs reduced clusterin levels in a dose-dependent and sequence-specific manner. Adjuvant treatment with murine clusterin ASOs after castration of mice bearing Shionogi tumors decreased clusterin levels, accelerated apoptotic tumor regression, and significantly delayed the recurrence of androgen-independent tumors. A human clusterin ASO targeting the translation initiation site and incorporating MOE-gapmer backbone (OGX-011) synergistically enhanced the cytotoxic effects of paclitaxel in human xenografts of prostate, renal cell, bladder, and lung cancer. Clusterin, is an anti-apoptosis protein upregulated in an adaptive cell survival manner by androgen ablation and chemotherapy that confers resistance to various cell death triggers. Suppression of clusterin levels using ASOs enhances cell death following treatment with androgen ablation, radiation, and chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig 2 A

Similar content being viewed by others

References

  1. Denis L, Murphy GP (1993) Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72:3888–3895

    Google Scholar 

  2. Oh WK, Kantoff PW (1998) Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160:1220–1229

    Google Scholar 

  3. Tannock IF, De Wit R, Berry WR et al. for the TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Google Scholar 

  4. Petrylak DP, Tangen CM, Hussain MH et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Google Scholar 

  5. Isaacs JT, Wake N, Coffey DS, Sandberg AA (1982) Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer. Cancer Res 42–48:2353

    Google Scholar 

  6. Miyake H, Tolcher A, Gleave ME (1999) Antisense Bcl-2 oligodeoxynucleotides delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. Cancer Res 59:4030–4034

    Google Scholar 

  7. Miyake H, Rennie P, Nelson C, Gleave ME (2000) Testosterone-repressed prostate message-2 (TRPM-2) is an antiapoptotic gene that confers resistance to androgen ablation in prostate cancer xenograft models. Cancer Res 60:170–176

    Google Scholar 

  8. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D (1990) Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50:2275–2282

    Google Scholar 

  9. Miyake H, Nelson C, Rennie P, Gleave ME (2000) Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141:2257–2265

    Article  Google Scholar 

  10. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox ME, Yu D, Miyake H, Gleave ME (2003) Castration-induced increased in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63:3575–3584

    Google Scholar 

  11. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME (1997) Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between androgen receptor and AP-1c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 272:17485–17494

    Google Scholar 

  12. Craft N, Shostak Y, Carey M, Sawyers C (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280–285

    Article  Google Scholar 

  13. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C (1998) Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 77:855–861

    Google Scholar 

  14. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL (1999) Mitogen-activated protein kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 19:5143–5154

    Google Scholar 

  15. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39

    Article  Google Scholar 

  16. Ettinger SL, Sobel R, Whitmore T, Akbari M, Bradley D, Gleave M, Nelson C (2004) Dysregulation of sterol response element binding proteins and downstream effectors in prostate cancer during progression to androgen-independence. Cancer Res 64:2212–21

    Google Scholar 

  17. Gimenez-Bonafe, P, Fedoruk MN, WhitmoreTG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC (2004) Up-regulation of the transcription factor YB-1 and its correlation with P-glycoprotein expression during prostate cancer tumor progression. Prostate 59:337–349

    Google Scholar 

  18. Gleave ME, Tolcher A, Miyake H, Beraldi E, Goldie J (1999) Progression to androgen-independence is delayed by antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5:2891–2898

    Google Scholar 

  19. Paterson R, Gleave M, Jone E, Zubovits J, Goldenberg SL, Sullivan LD (1999) Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormone therapy. Mol Urol 3:277–286

    Google Scholar 

  20. McDonnell TJ, Troncoso P, Brisby SM, Logothetis CL, Chung LWK, Hsieh JT et al. (1992) Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940–6944

    Google Scholar 

  21. Colombel M, Symmans F, Gil S, O’Toole KM, Choplin D, Benson M et al. (1993) Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390–400

    Google Scholar 

  22. Raffo AJ, Periman H, Chen MW, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438–4445

    Google Scholar 

  23. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, Van Elsas A, Muller M et al. (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232–234

    Google Scholar 

  24. Miyake H, Tolcher A, Gleave ME (2000) Antisense bcl-2 oligodeoxynucleotides enhance taxol chemosensitivity and synergistically delays progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. J Natl Cancer Inst 92:34–41

    Article  Google Scholar 

  25. Rocchi P, So A, Kojima S. Beraldi E, Fazli L, Gleave ME (2004) Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone refractory prostate cancer. Cancer Res 64:6595–6602

    Google Scholar 

  26. Nickerson T, Miyake H, Gleave ME, Pollak M (1999) Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor binding proteins. Cancer Res 59:3392–3395

    Google Scholar 

  27. Miyake H, Pollak, Gleave ME (2000) Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60:3058–3064

    Google Scholar 

  28. Tenniswood M, Wang Z, Lakins J, Morrissey C, O’Sullivan J, Tang H (1998) Clusterin in the male reproductive tract. J Androl 19:508–516

    Google Scholar 

  29. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J (2000) Apolipoprotein J (clusterin) and Alzheimer’s disease. Microsc Res Tech 50:305–315

    Google Scholar 

  30. Rosenberg ME, Silkensen J (1995) Clusterin and the kidney. Exp Nephrol 3: 9–14

    Google Scholar 

  31. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM, Sensibar JA (1997) Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3:1701–1711

    Google Scholar 

  32. Cervellera M, Raschella G, Santilli G, Tanno B, Ventura A, Mancini C, Sevignani C, Calabretta B, Sala A (2000) Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem 275:21055–21060

    Article  Google Scholar 

  33. Kyprianou N, English HF, Davidson NE, Isaacs JT (1991) Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162–166

    Google Scholar 

  34. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK (2000) Overexpression of clusterin in human breast carcinoma. Am J Pathol 157:393–399

    Google Scholar 

  35. Wellmann A, Thieblemont C, Pittaluga S, Sakai A, Jaffe ES, Siebert P, Raffeld M (2000) Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96:398–404

    Google Scholar 

  36. Parczyk K, Pilarsky C, Rachel U, Koch-Brandt C (1994) Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 120:186–188

    Google Scholar 

  37. Montpetit ML, Lawless KR, Tenniswood M (1986) Androgen-repressed messages in the rat ventral prostate. Prostate 8:25–36

    Google Scholar 

  38. Budendorf L, Kolmer M, Kononen J et al. (1999) Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue arrays. J Natl Cancer Inst 91:1758–1764

    Article  Google Scholar 

  39. Kyprianou N, English HF, Isaacs JT (1990) Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748–3753

    Google Scholar 

  40. Tenniswood MP, Guenette RS, Lakins J, Mooibroek M, Wong P, Welsh JE (1992) Active cell death in hormone-dependent tissues. Cancer Metastasis Rev 11:197–220

    Article  Google Scholar 

  41. Danik M, Chabot JG, Mercier C, Benabid AL, Chauvin C, Quirion R, Suh M (1991) Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc Natl Acad Sci U S A 88:8577–8581

    Google Scholar 

  42. Connor J, Buttyan R, Olsson CA, D’Agati V, O’Toole K, Sawczuk IS (1991) SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int 39:1098–1103

    Google Scholar 

  43. Ho SM, Leav I, Ghatak S, Merk F, Jagannathan VS, Mallery K (1998) Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am J Pathol 153:131–139

    Google Scholar 

  44. Schwochau GB, Nath KA, Rosenberg ME (1998) Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 53:1647–1653

    Article  PubMed  Google Scholar 

  45. French LE, Sappino AP, Tschopp J, Schifferli JA (1992) Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J Clin Invest 90:1919–1925

    Google Scholar 

  46. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ, Boothman DA (2000) Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci U S A 97:5907–5912

    Google Scholar 

  47. Koch-Brandt C, Morgans C (1996) Clusterin: a role in cell survival in the face of apoptosis? Prog Mol Subcell Biol 16:130–149

    Google Scholar 

  48. Michel D, Chatelain G, North S, Brun G (1997) Stress-induced transcription of the clusterin/apoJ gene. Biochem J 328:45–50

    CAS  PubMed  Google Scholar 

  49. Miyake H, Rennie P, Nelson C, Gleave ME (2000) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2 (TRPM-2), in prostate cancer xenograft models. Cancer Res 60:2547–2554

    Google Scholar 

  50. Zellweger T, Chi K, Miyake H, Adomat H, KiyamaS, Skov K, Gleave M (2002) Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8:3276–3284

    Google Scholar 

  51. Criswell T, Klokov D, Beman M, Lavik JP, Boothman DA (2003) Repression of IR-inducible clusterin expression by the p53 tumour suppression protein. Cancer Biol Ther 2:372–380

    Google Scholar 

  52. Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, Mancina R, Gelmini S, Serio M, Villari D, Vannelli GB, Colli E, Adorini L, Maggi M (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 150: 591–603

    Google Scholar 

  53. Jones SE, Jomary C (2002) Clusterin. IntJBiochem Cell Biol 34:427–431

    Google Scholar 

  54. Wilson MR, Easterbrook-Smith SB (2000) Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 25:95–98

    Article  CAS  PubMed  Google Scholar 

  55. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR (1999) Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274:6875–6881

    Article  Google Scholar 

  56. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597–608

    Google Scholar 

  57. Rouayrenc JF, Boise LH, Thompson CB, Privat A, Patey G (1995) Presence of the long and the short forms of Bcl-X in several human and murine tissues. C R Acad Sci III 318:537–540

    Google Scholar 

  58. Minn AJ, Boise LH, Thompson CB (1996) Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J Biol Chem 271:6306–6312

    Google Scholar 

  59. Sintich SM, Steinberg J, Kozlowski JM, Lee C, Pruden S, Sayeed S, Sensibar JA (1999) Cytotoxic sensitivity to tumor necrosis factor alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate 39:87–93

    Google Scholar 

  60. Miyake H, Hara I, Kamidono S, Gleave ME, Eto H (2003) Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep 10:469–473

    Google Scholar 

  61. Wong P, Pineault J, Lakins J, Taillefer D, Leger J, Wang C, Tenniswood M (1993) Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J Biol Chem 268:5021–5031

    Google Scholar 

  62. Lakins J, Bennett SA, Chen JH, Arnold JM, Morrissey C, Wong P, O’Sullivan J, Tenniswood M (1998) Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J Biol Chem 273:27887–27895

    Google Scholar 

  63. Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH, Strickland DK, Argraves WS (1995) Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J Biol Chem 270:13070–13075

    Google Scholar 

  64. Sensibar JA, Sutkowski DM, Raffo A et al. (1995) Prevention of cell death induced by tumor necrosis factor in alpha LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 55:2431–2437

    Google Scholar 

  65. Miyake H, Hara I, Gleave ME, Eto H (2004) Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 61: 318–323

    Google Scholar 

  66. Pins MR, Fiadjoe JE, Korley F, Wong M, Rademaker AW, Jovanovic B, Yoo TK, Kozlowski JM, Raji A, Yang XJ, Lee C (2004) Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis 7:243–248

    Google Scholar 

  67. July L, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50:179–188

    Article  Google Scholar 

  68. Miyake H, Hara I, Kamidono S, Gleave ME (2001) Synergistic chemosensitization and inhibition of tumour growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 7:4245–4252

    Google Scholar 

  69. Zellweger T, Miyake H, July L, Akbari M, Kiyama S, Gleave ME (2001) Chemosensitization of a human renal cell cancer model by antisense TRPM-2 oligodeoxynucleotides both in vitro and in vivo. Neoplasia 3:1–8

    Google Scholar 

  70. July LV, Beraldi E, So AI, Evans K, English J, Fazli L, Gleave ME (2004) Nucleotide-based therapies targeting clusterin chemosensitizes human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 3:223–232

    Google Scholar 

  71. Crooke ST (1993) Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329–376

    Google Scholar 

  72. Saijo Y, Perlaky L, Wang H, Busch H (1994) Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol Res 6:243–249

    Google Scholar 

  73. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2:668–675

    Google Scholar 

  74. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia B, Gleave ME (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-o-(2-methoxy) ethyl chemistry. J Pharmacol Exp Ther 298:934–940

    Google Scholar 

  75. Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF (2000) Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther 292:468–479

    Google Scholar 

  76. Miyake H, Chi K, Gleave ME (2000) Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6:1655–1663

    Google Scholar 

  77. Trougakso IP, So A, Jansen B, Gleave ME, Gonos ES (2004) Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64:1834–1842

    Google Scholar 

  78. Kyprianou N, King ED, Bradbury D, Rhee JG (1997) Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70:341–348

    Google Scholar 

  79. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, Gleave ME (2003) Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int 92:463–469

    Google Scholar 

  80. Chi KN, Eisenhauer E, Fazli L, Jones EC, Powers J, Ayers D, Goldenberg SL, Gleave ME (2004) A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2′methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. J Clin Ocol, Proceedings of American Society of Clinical Oncology, 2004

  81. Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wacheck V, Gleave ME, Pehamberger H, Jansen B (2005) Clusterin regulates drug-resistance in melanoma cells.J Invest Dermatol (in press)

Download references

Author information

Authors and Affiliations

  1. Division of Urology, University of British Columbia, D-9, 2733 Heather Street, Vancouver, British Columbia , V5Z 3J5, Canada

    Martin Gleave

  2. The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada

    Hideaki Miyake

Authors
  1. Martin Gleave
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Hideaki Miyake
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Martin Gleave.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gleave, M., Miyake, H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 23, 38–46 (2005). https://doi.org/10.1007/s00345-004-0474-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-004-0474-0

Keywords